Pyridoxine dipalmitate

We are Pyridoxine dipalmitate CAS:635-38-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 635-38-1
Product Name: Pyridoxine dipalmitate
Other Name:
Pyridoxine dipalmitate
(4-hexadecanoyloxy-5-hydroxy-6-methylpyridin-3-yl) hexadecanoate
5-Hydroxy-6-methyl-3,4-pyridinedimethanol dipalmitate
Pyridoxin-3,4-dipalmitat
Vitamin B6 dipalmitate
 
Melting Point: 87-91ºC
Molecular Formula: C40H71NO5
Molecular Weight: 645.99500
Exact Mass: 645.53300
PSA: 85.72000
LogP: 12.14460
 
Specification
Appearance: White crystal powder
Solubility: Conforms
Identification: Conforms
Melting point: 86.0-90.0℃
Loss on drying: ≤0.3%
Heavy metals: ≤0.002%
Assay: ≥98.0%
Microbiological Test
Bacteria: ≤300CPU
Fungi: ≤100CPU
Reference addition: 0.5~2.0% 
 
Application
It is mainly used to prevent rough skin, acne and sunburn. Also suitable for preventing and treating seborrheic alopecia, skin inflammation, general acne, seborrheic eczema and other cosmetic preparations. It can be made into creams, lotions, nutritious shampoos and conditioners. Generally used in combination with other vitamins.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

Pyridoxine dipalmitate


Related News: ICIG companies currently employ more than 3,000 people and operate 15 manufacturing facilities in Europe and the United States.Cloruro de (S) -1-fenil-3,4-dihidro-1H-isoquinolina-2-carbonilo CAS:1195949-26-8 ICIG companies currently employ more than 3,000 people and operate 15 manufacturing facilities in Europe and the United States.1,4-naftalenodiona CAS:130-15-4 “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.Coenzyme Q10 “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical.

Related Products
Product Name
Boc-D-prolinol View Details
4-Bromo-2-fluorobenzyl bromide View Details
Methyl 2-Oxoindoline-6-carboxylate View Details
5′-Tosyl Adenosine manufacturer Oxytocin acetate manufacturer phenyl N-[4-[4-(4-hydroxyphenyl)piperazin-1-yl]phenyl]carbamate manufacturer N-(3-Acetyl-2-hydroxyphenyl)acetamide manufacturer Ethyl 5-oxo-1-phenyl-2-pyrazoline-3-carboxylate manufacturer